IDXX Shorts Creep Higher as Analysts Trim Targets

IDEXX Laboratories heads into the back half of June with a quiet but persistent tension: short sellers are rebuilding positions even as the stock posts its best monthly gain in some time.

The short interest story is modest in absolute terms but directionally notable. At 2.8% of free float, the short position is not large — but it has climbed 8.3% over the past week and 6.3% over the past month, the steadiest buildup since early spring. That incremental pressure is worth tracking against a stock that has recovered 8.4% over the past month to close at $573. The lending market offers no support for a squeeze thesis: availability is extraordinarily loose at roughly 2,000% of shares borrowed, meaning there are around 55 million shares available to lend against barely 2.2 million shorted. Cost to borrow has fallen sharply too, dropping 27% on the week to just 0.39% — near generational lows for this name. Options positioning leans bullish relative to recent norms. The put/call ratio is running at 0.59, about 1.2 standard deviations below its 20-day average of 0.63, and close to the lowest reading of the past year at 0.50. That combination — shorts adding quietly while options traders tilt toward calls — describes a stock where the bears are cautious but not panicked, and the bulls remain in control of near-term sentiment.

The Street's direction of travel has been one-way: lower targets, mixed conviction. Since February, nearly every analyst who has moved has trimmed their price objective. UBS cut to $640 in late April while holding Neutral. Citi initiated at Neutral with a $650 target in mid-April. Stifel lowered to $675 from $775 in late March while keeping its Buy rating. The consensus mean target is $709, implying roughly 24% upside from current levels — a gap that looks wide but reflects how far the stock has retreated from its highs rather than a sudden burst of bullishness. Note that the analyst data here is somewhat stale (latest action reported early May), so the current consensus may have shifted further. Valuation remains elevated: the P/E runs at 37x and price-to-book at 18.5x, both drifting higher on the month as the stock has recovered. The EV/EBITDA at 26x is broadly flat over 30 days. Factor scores are uninspiring in aggregate — forward EPS growth is ranked in the bottom quintile of the universe, and the earnings yield rank is also weak, reflecting a premium multiple with decelerating growth expectations. EPS surprise and dividend scores are mid-table.

Institutional ownership is stable and concentrated in index and quality-oriented hands. BlackRock holds 10.6% and made a small addition as recently as May. State Street and Geode both added modestly in the same window. The more interesting move comes from Capital Research and Management, which added nearly 685,000 shares as of March 31 — a meaningful build by an active manager known for long-duration quality positions. Fundsmith, another quality-focused holder at 1.9%, has not moved its stake. The insider picture is quiet: the net 90-day activity is a handful of routine awards and one EVP sale in early June for roughly $161,000, all low significance.

Earnings history adds a note of caution heading into the next print, scheduled for August 7. The two most recent releases delivered negative one-day reactions of 0.6% and 7.0% respectively, and the five-day drift after the February quarter was also negative at 7.6%. The most recent May quarter recovered 2.7% over five days after an initial dip, suggesting the stock can recapture ground post-earnings — but the initial reaction has more often been a seller's moment than a buyer's. IDXX's closest correlated peers — STE, ISRG, and GMED — all fell 3–6% on the week while IDXX slipped just 1%, suggesting relative resilience or simply less selling pressure given its already-compressed positioning.

The setup heading into August is therefore one to watch: a stock that has quietly recovered 8% on the month, with shorts adding at the margin, analysts anchoring targets well above current prices but trimming steadily, and an earnings track record that has punished buyers in the initial session more often than not.